Rafael Penades
Overview
Explore the profile of Rafael Penades including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
730
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corbera S, Kurtz M, Achim A, Agostoni G, Amado I, Assaf M, et al.
Eur Psychiatry
. 2025 Jan;
68(1):e9.
PMID: 39812093
In the last decades, research from cognitive science, clinical psychology, psychiatry, and social neuroscience has provided mounting evidence that several social cognitive abilities are impaired in people with schizophrenia and...
2.
Penades R, Forte M, Mezquida G, Andres C, Catalan R, Segura B
Healthcare (Basel)
. 2024 Nov;
12(21).
PMID: 39517406
Cognitive impairment is a core feature of schizophrenia, affecting attention, memory, and executive function and contributing significantly to the burden of the disorder. These deficits often begin before the onset...
3.
Almodovar-Paya C, Paris-Gomez I, Latorre-Guardia M, Guardiola-Ripoll M, Catalan R, Arias B, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2024 Oct;
136():111175.
PMID: 39426559
Cognitive remediation therapy (CRT) demonstrates potential in enhancing cognitive function in schizophrenia (SZ), though the identification of molecular biomarkers remains challenging. The Neuritin-1 gene (NRN1) emerges as a promising candidate...
4.
Forte M, Oliva V, De Prisco M, Garriga M, Bitanihirwe B, Alameda L, et al.
Neurosci Biobehav Rev
. 2024 Oct;
167:105913.
PMID: 39362417
Schizophrenia (SZ) is a severe mental health condition involving gene-environment interactions, with obstetric complications (OCs) conferring an elevated risk for the disease. Current research suggests that OCs may exacerbate SZ...
5.
Clougher D, Forte M, Mezquida G, Sanchez-Torres A, Serra-Navarro M, Penades R, et al.
Eur Neuropsychopharmacol
. 2024 Jul;
85:66-77.
PMID: 39013243
Emotional intelligence (EI) and neurocognition (NC) impairments are common in first-episode psychosis (FEP), yet their evolution over time remains unclear. This study identified patient profiles in EI and NC performance...
6.
Penades R, Almodovar-Paya C, Garcia-Rizo C, Ruiz V, Catalan R, Valero S, et al.
J Psychiatr Res
. 2024 Mar;
173:166-174.
PMID: 38537483
Although cognitive remediation therapy (CRT) produces cognitive benefits in schizophrenia, we do not yet understand whether molecular changes are associated with this cognitive improvement. A gene central to synaptic plasticity,...
7.
Costas-Carrera A, Verdolini N, Garcia-Rizo C, Mezquida G, Janssen J, Valli I, et al.
Psychol Med
. 2023 Nov;
54(7):1339-1349.
PMID: 38014924
Background: Patients with a first episode of psychosis (FEP) display clinical, cognitive, and structural brain abnormalities at illness onset. Ventricular enlargement has been identified in schizophrenia since the initial development...
8.
Hidese S, During S, Penades R
Front Psychiatry
. 2023 Sep;
14:1261696.
PMID: 37674555
No abstract available.
9.
Penades R, Wykes T
Br J Psychiatry
. 2023 May;
223(1):319-320.
PMID: 37194957
Cognitive remediation is currently recommended to treat cognitive and functional impairments in patients with schizophrenia. Recently, treatment of negative symptoms has been proposed as a new target for cognitive remediation....
10.
Marquez-Arrico J, Gonzalez-Sanchez A, Navarro J, Penades R, Adan A
J Clin Med
. 2022 Nov;
11(22).
PMID: 36431125
Comorbidity of substance use disorders (SUD) and severe mental illness (SMI) is highly frequent in patients, the most common diagnoses being schizophrenia (SZ), bipolar disorder (BD) and major depressive disorder...